Press release

Results of the Galenica Group for the first half of 2014

Tuesday, 12 August 2014, ↓ directly to download

The Galenica Group is targeting an increase in profits for the 19th consecutive year in 2014

_The continuing pressure on drug prices and margins, and the negative development of the various healthcare markets worldwide had a negative impact on the business activities of the Galenica Group. Despite this, all Business sectors were able to increase their earnings before interest and taxes (EBIT). The Group’s management has set itself the target of increasing Group net profit on a comparable basis for 2014, both before and after deduction of minority interests, for the 19th consecutive year.
The consolidated net sales of the Galenica Group in the first half of 2014 totalled CHF 1,661.5 million (+0.8%). On a comparable basis and excluding one-time effects, net profit increased by 7.9% to CHF 149.6 million before minority interests and by 6.1% to CHF 134.7 million after deduction of minority interests.

_Sales of Ferinject® rose by 17.0% to CHF 86.2 million, while the number of units (100 mg) sold grew by 25.7%. Venofer® generated sales of CHF 57.6 million (-2.9%). The pressure resulting from ISS products and Ferinject® substitution effects has decreased significantly year-on-year. The new phosphate binder Velphoro® was launched in the USA by partner Fresenius Medical Care North America in March and has seen very positive sales growth. At the end of June, the European Committee for Medicinal Products for Human Use (CHMP) recommended marketing authorisation for Velphoro®; the final decision is expected in autumn 2014.

_The renewed drug price reductions imposed by the federal government and the associated decline in the Swiss pharmaceutical market, as well as the extremely mild flu season, had a strong impact on activities in Switzerland in the first half of 2014. Despite these difficult market conditions, the three Business sectors Logistics, Retail and HealthCare Information managed to generate an increase in EBIT year-on-year.

EBIT, EBITDA and consolidated net profit of the Galenica Group

EBIT, EBITDA and consolidated net profit of the Galenica Group

EBIT, EBITDA and consolidated net profit of the Galenica Group

Click on the image to enlarge the picture.

Read more

Galenica is a diversified Group active throughout the healthcare market which, among other activities, develops, manufactures and markets pharmaceutical products, runs pharmacies, provides logistical and database services and sets up networks. With its two Business units Vifor Pharma and Galenica Santé, the Galenica Group enjoys a leading position in all its core business activities. A large part of the Group’s income is generated by international operations. Galenica is listed on the Swiss Stock Exchange (SIX Swiss Exchange, GALN, security number 1,553,646).

Contact

Julien Vignot

Julien Vignot

Head Investor Relations


Galenica Ltd.

Investor Relations
Untermattweg 8
CH-3027 Bern

Phone:
+41 58 852 81 11
Fax:
+41 58 852 81 12

Christina Hertig

Christina Hertig

Head of Corporate Communications


Galenica Ltd.

Corp. Communications
Untermattweg 8
CH-3027 Bern

Phone:
+41 58 852 85 17
Fax:
+41 58 852 85 58

Send link

Send as link



Links